© 2022 MJH Life Sciences and CGTLive™. All rights reserved.
© 2022 MJH Life Sciences™ and CGTLive™. All rights reserved.
May 05, 2022
Veeral S. Sheth, MD, MBA, Director of Clinical Research at the University of Retina and Macula Associates, discusses advanced therapies for retinal diseases.
December 13, 2021
Following GS030 optogenetic therapy, the first treated patient was able to locate and count objects on a table and could identify crosswalks in the street.
December 06, 2021
Findings from the phase 2 INFINITY trial identified dose-dependent safety outcomes of ADVM-022 in patients with diabetic macular edema.
August 23, 2021
The 2-dose vaccine has been approved for use 9 months after its Emergency Use Authorization (EUA).
May 07, 2021
A podcast interview with study author Paul Yang, MD, PhD, on the current research and future implementation of the agent.
March 30, 2021
A budget impact analysis suggest the burgeoning drug class may not be as available as it could be for sickle cell patients.
February 12, 2021
Descriptive findings from the phase 1/2 study allude to promise for the gene therapy in the rare pediatric disorder.
New phase 2/3 findings meet investigators' hypotheses on the gene therapy's mixed benefits for heparan sulfate reduction.
The AAV-based gene therapy was well-tolerated and showed enough promising effect to warrant further investigation, researchers reported.
Investigators observed sustained, dose-dependent benefits for young patients at 24 months.